Why choose the Lions Eye Institute
The Lions Eye Institute offers a full range of eye health care services. As a not for profit organisation all surpluses directly support our world-leading medical research. By choosing the Lions Eye Institute, you are helping to eradicate blindness.
Established in 1983 The Lions Eye Institute quickly became a global centre for ophthalmological care and first-class scientific research into the prevention of blindness.
Our activities are underpinned by a continuous improvement program and worldwide collaborative research as we strive to achieve our Vision – To prevent and cure blindness and eye disease.
Our Clinical Services are internationally recognized for providing high-quality care, a dedicated, passionate and professional team, continued investment in the latest equipment and technology, ongoing ISO 9001 accreditation and strong patient satisfaction ratings.
Our scientists work in close association with our clinicians to bring laboratory generated ideas and techniques to the level where they can be of benefit to people suffering blinding eye conditions. Our patients benefit by receiving the most advanced treatments available anywhere in the world.
The Lions Eye Institute has achieved a number of remarkable breakthroughs in our drive to eradicate blindness. Read more about our key achievements below.
Throughout its history the Lions Eye Institute has posted a number of remarkable breakthroughs in its drive to eradicate blindness worldwide. Achievements include:
- A human gene therapy treatment for wet Age-Related Macular Degeneration (AMD). Wet AMD is the most common cause of blindness in the developed world and costs up to $6 billion worldwide each year.
- Establishing a link between chronic viral infection and the development of the second most common autoimmune disease – Sjogren’s Syndrome (SS). SS is a chronic condition that mainly affects women and causes a range of symptoms, including dry eyes.
- An innovative treatment for open angle glaucoma – the most common type of glaucoma. The XEN Gel Stent developed at the LEI is 6mm long and the width of a human hair.
- Using data from the Busselton Healthy Ageing Study to identify an important link – that spending more time outdoors reduces the risk of myopia but increases the risk of skin cancer. More research is being done to identify optimum and safe levels of sun exposure for eye health.
- Developing personalised cell-based therapy to treat macular and retinal degenerations.
- World-first development of a retinal vein bypass treatment for retinal vein blockages
- Operating one of Australia’s largest ophthalmic practices offering treatments for the full range of eye conditions including glaucoma, cataracts, macular degeneration, retinal disorders and laser refractive surgery.
- Opening the first and leading refractive centre in Western Australia. The Lions Laser Vision Centre was the first to perform laser PRK surgery in Australia in 1991, the first to perform LASIK in Western Australia in 1996 and still the only accredited laser vision centre in WA. Our clinic is the only one in Perth to use the world’s fastest and most advanced excimer laser source, the Schwind 1050RS.
- Establishing the Lions Eye Bank – the only facility in Western Australia that coordinates the collection, processing and distribution of eye tissue for transplantation.
- A commitment to the highest standards of quality patient care and research excellence. The LEI’s Clinical Services have achieved national accreditation standards every year since 2006.
- Establishing one of the largest ophthalmological clinical trials centres anywhere in the world.
To facilitate continued investigation into blinding eye disease, funds raised through the commercialisation of innovative research developed at LEI are channelled back into other promising research projects.
LEI’s longevity and internationally recognised reputation is testament to the excellence of its research and clinical capabilities. Research groups at LEI are involved in both national and international collaborative programs. The Institute actively participates in numerous clinical trials which enable scientists, ophthalmologists and pharmaceutical companies to develop new treatments for eye disease.